What other biotechs are you guys looking at these days?
GATTEX (teduglutide) for treatment of SBS should be approved this year (despite the cancer scare that arose and cut price almost in half). They have also published good results from their P3 trail for NPS558 for hypoparathyroidism.
Rumor is that Takeda may be interested in NPS once GATTEX approved, as they bought NYCOMED on their european approval of teduglutide. Even at its current price, there's still good upside without buyout.